FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to DNA-aptamers to this human (Pol eta) DNA polymerase and to a method for using DNA-aptamers to inhibit Pol eta activity. Aptamers are nucleic acids which show high affinity for the target substance and inhibitors of activity of biological molecules.
EFFECT: invention allows to inhibit polymerase activity Pol eta, which is achieved by interaction of DNA-aptamers with Pol eta molecule.
1 cl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DNA APTAMERS TO HUMAN PrimPol PRIMASE AND DNA POLYMERASE | 2020 |
|
RU2770691C2 |
| DNA-APTAMER WITH HIGH AFFINITY TO INTERLEUKIN-6 PROTEIN | 2023 |
|
RU2814541C2 |
| METHOD FOR CREATION AND SELECTION OF THE LIBRARY OF MODIFIED APTAMERS | 2016 |
|
RU2652952C1 |
| DNA-APTAMER BINDING AN EXTRACELLULAR DOMAIN OF EGFR | 2018 |
|
RU2700097C1 |
| COMPLEMENT-BINDING APTAMERS AND C5 AGENTS APPLICABLE FOR TREATING OCULAR DISORDERS | 2007 |
|
RU2477137C2 |
| THERMAL DISSOCIATION METHOD FOR SELECTION OF DNA-APTAMERS | 2019 |
|
RU2723373C1 |
| DNA-APTAMERS INTERACTING WITH PROTHROMBIN | 2018 |
|
RU2703799C1 |
| METHOD FOR DETERMINING SUBSTRATE EFFICIENCY OF DEOXYURIDINE TRIPHOSPHATES DERIVATIVES FOR DNA POLYMERASES BY PRIMER COMPLETION REACTION | 2019 |
|
RU2731739C1 |
| ANTICOAGULANT WITH DIRECT ACTION BASED ON MODULAR BIVALENT DNA OF APTAMER SELECTIVE TO THROMBIN | 2016 |
|
RU2631829C1 |
| APTAMERIC THERAPEUTIC AGENTS APPLICABLE FOR TREATING COMPLEMENT-RELATED DISORDERS | 2006 |
|
RU2406507C2 |
